Context: Gastric bypass surgery is the most commonly performed bariatric surgical procedure in the United States. Variable weight loss following this relatively standardized intervention has been reported. To date, a method for reliable profiling of patients who will successfully sustain weight loss for the long term has not been established. In addition, the mechanisms of action in accomplishing major weight loss as well as the explanation for the variable weight loss have not been established. Objective: To examine whether gene expression in perioperative omental adipose is associated with gastric bypass-induced weight loss. Design: Cross-sectional study of gene expression in perisurgical omental adipose tissues taken/available at the time of operation and total excess weight loss (EWL). Subjects: Fifteen overweight individuals who underwent Roux-en-Y gastric bypass (RYGB) surgery at the University of California Davis Medical Center (BMI: 40.6-72.8 kg/m 2 ). Measurements: Body weight before and following weight stabilization 18-42 months after surgery. Perioperative omental adipose RNA isolated from 15 subjects was hybridized to Affymetrix HG-U133A chips for 22 283 transcript expression measurements. Results: Downstream analysis identified a set of genes whose expression was significantly correlated with RYGB-induced weight loss. The significant individual genes include acyl-coenzyme A oxidase 1 (ACOX1), phosphodiesterase 3A cGMP-inhibited (PDE3A) and protein kinase, AMP-activated, beta 1 non-catalytic subunit (PRKAB1). Specifically, ACOX1 plays a role in fatty acid metabolism. PDE3A is involved in purine metabolism and hormone-stimulated lipolysis. PRKAB1 is involved in adipocytokine signaling pathway. Gene network analysis revealed that pathways for glycerolipid metabolism, breast cancer and apoptosis were significantly correlated with long-term weight loss. Conclusion: This study demonstrates that RNA expression profiles from perioperative adipose tissue are associated with weight loss outcome following RYGB surgery. Our data suggest that EWL could be predicted from preoperative samples, which would allow for informed decisions about whether or not to proceed to surgery.
Introduction
The prevalence of obesity has remarkably increased during the last few decades. The pathophysiology of obesity has been increasingly identified in recent years including a direct relationship of body mass index (BMI) and the relative risk of death. 1 Multiple conditions or diseases have been shown to occur with increasing frequency with progressively severe obesity including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea and many others. 2 The relative risk for multiple cancers among the obese has been reported and recently confirmed. 3, 4 Despite all preventive and therapeutic attempts, long-term maintenance of weight loss often fails. Surgical procedures have been considered the most reliable method of accomplishing weight loss and associated reduction in pathology long term. 5 Roux-en-Y gastric bypass (RYGB) is the most commonly performed bariatric surgical procedure in the United States. Criteria for surgical intervention were established by a National Institute of Health (NIH) consensus conference in 1991 and consist of BMI440 kg/m 2 or 435 kg/m 2 in the presence of significant comorbidities. 6 In addition to weight loss, induction of improvement or long-term remission of comorbidities, particularly type 2 diabetes, hypertension, dyslipidemia and obstructive sleep apnea, have been reported. Recent reports of improved survival and diminished incidence of death secondary to cancer have been reported. 5, 7 Even though the average gastric bypass patient loses significant weight postoperatively, individual weight losses vary considerably. Pories reports excess weight loss (EWL) 10 years following gastric bypass to range from 0.9 to 103%, also demonstrating the wide range of postoperative weight loss. It is estimated that 10-20% of RYGB patients fail to achieve sufficient weight loss or maintain weight loss to be considered successful outcomes. 8 Failure rates as high as 43% have been reported among patients with greater preoperative BMI. 9 This high degree of variability of the postoperative weight loss provides an opportunity for investigation into the mechanisms by which weight loss is achieved following RYGB. The traditional explanation for induction of weight loss post-RYGB has been a diminished nutrient/energy intake as a result of the gastric restriction created by the small gastric pouch as well as a variable component of malabsorption. There is increasing evidence, however, that alterations in gut hormone release involved in signaling essential nervous system regulation of energy balance play a role in achieving weight loss. [10] [11] [12] Genetics plays a major role in the development of obesity. While the proportion of the bariatric surgical population that experiences obesity as the result of a defined genetic syndrome/deletion has been estimated to be 5%, it is possible that genetic heterogeneity plays a role in the etiology of the obesity as well as the outcome following RYGB. Genetic heterogeneity is known to cause clinical heterogeneity in many diseases. The effects of genetics on weight loss after RYGB are not well understood. We hypothesize that underlying genetic differences influence the heterogeneity of long-term response to RYGB.
Gene expression profiling through microarray techniques enables us to study the roles of thousands of known and unknown genes simultaneously by investigating gene expression patterns in different conditions. Studies have shown that adipose tissue-expressed genes that influence primarily obesity and its comorbidities can be identified by mRNA expression profiles. 13, 14 We herein hypothesize that expressed gene levels in adipose tissues predict weight response to RYGB surgery. The objective of this study is to assess the effects of genetics on RYGB-induced weight loss. We investigate whether there are genes whose expression is correlated with RYGB-induced weight loss. Our data provide evidence for the genetic association of RYGB-induced weight loss with genetic variants at the molecular level. We should note that this study is not to establish the mechanisms by which RYGB surgery influences weight loss but to demonstrate the feasibility of gene expression profiles as a means for biomarker discovery predictive of RYGB outcomes. Those biomarkers have potential as predictors that assess long-term efficacy of RYGB (weight loss maintenance), which eventually leads to clinical use.
Methods
Roux-en-Y gastric bypass patients Twenty-seven participants consented to protocols approved by the University of California Davis Institutional Review Board. Selection criteria were individuals 18-60 years old with BMI X40 kg/m 2 or BMI X35 kg/m 2 with associated diabetes. Those patients had failed conventional weight loss measures and the attending surgeons made a decision to perform RYGB surgery based on the standard criteria (prior abdominal surgery, BMI, patient preference and so on). No direct dietary or physical activity intervention was carried out before surgery, although patients were advised to avoid further weight gain before operation. All patients were seen a minimum of twice and at most three times before surgery. Body weights at the outset of the assessment and at the immediate preoperative interval were recorded. No patient experienced as much as a 5% (total body weight) preoperative weight loss; changes of physical activity were minimal.
Statement of ethics
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. 
Body weight measurements
). Excess body weight was estimated by excess weight over the ideal body weight. The percentage of EWL (%EWL) following the operation was calculated according to the formula (%EWL ¼ 100% Â (excess body weight before surgery-excess body weight after surgery)/(excess body weight before surgery)).
RNA sample preparation and hybridizations
Ten grams of omental adipose tissue were harvested from each participant for mRNA samples. RNA was purified with TRIZOL reagent (Gibco/BRL, Grand Island, NY, USA) to yield Gastric bypass-induced weight loss and gene expression profiles K Kim et al 10-50 mg of total RNA per gram of adipose. Samples were quantified and run on a 1% denaturing gel to confirm integrity. For the microarray study, we selected the most informative individuals from total 27 subjects availableF8 subjects who had the lowest %EWL (bottom 30%) who were less sensitive to RYGB with respect to weight loss and seven subjects who had the highest %EWL (top 26%) who were more sensitive to RYGB. Hereafter, we refer to these groups as %EWL-low and %EWL-high, respectively. Omental adipose mRNA isolated from the selected 15 subjects was hybridized to Affymetrix HG-U133A oligonucleotide chips, each containing 22 283 transcripts, according to a protocol developed by Affymetrix co (http://www.affymetrix.com/products/arrays/specific/ht_hgu133_ap.affx).
Statistical quality control
First, box plot analysis of intensities was preformed to analyze the overall intensities of all probes across the array (see Figure 1 ). The box is drawn from the 25th and 75th percentiles in the distribution of intensities. The median, or 50th percentile, is drawn inside the box. The whiskers (lines extending from the box) describe the spread of the data within the 10th and 90th percentiles. The dots display any points beyond the 10th and 90th percentiles. The box plot showed that all arrays were similar in range. Second, we performed quality control analysis using the deleted residuals method to test whether a chip was homogeneous with other chips. 15 The probability density function for the deleted residuals for a gene should follow a t-distribution with nÀ2 degrees of freedom, where 'n' is the number of chips in the group, if a chip was homogeneous. The deleted residuals for each gene on each chip were calculated by taking the observed value of a gene on a chip subtracting the mean for the gene across all other chips divided by the standard deviation of the mean for the gene across all the other chips. The difference of the observed data from the expected t-distribution was statistically tested using Kolmogorov-Smirnov test. The significance of the difference was determined based on the P-value that was associated with the Kolmogorov-Simirnov D statistic. When the P-value was less than 0.20, we concluded that the data did not come from the t-distribution. Note that we declared significance at the higher level, 0.20, rather than the often used 0.05 level due to the small sample size. None of the chips were significantly different (Po0.20) from the expected t-distribution. As a result, we included all 15 arrays in the further analyses. The quality control procedure using the deleted residuals method was performed using HDBStat! Software (http://www.ssg.uab.edu/hdbstat/).
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Statistical analysis
For the mRNA transcript level data, the CEL files had been processed with dChip. 16 Before analysis, data preprocessing was performed by quantile-quantile normalization to remove variability among chips that was unrelated to biological variation. The scores of EWL were dichotomized according to their group membership of either %EWL-high or %EWL-low. intensities. The whiskers (lines extending from the box) describe the spread of the data within the 10th and 90th percentiles. The dots display any points beyond the 10th and 90th percentiles.
Chip number
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The dichotomized outcomes were used for discriminate analysis to identify genes whose expression differentiates %EWL-high from %EWL-low. For the discovery of genes of differential expression, we used a two-fold analysis approach. First, we applied unequal variance t-test (Welch t-test) to screen out genes whose expression significantly differentiated between %EWL-high and %EWL-low. Second, partial correlation coefficients were calculated to assess the magnitude of the linear association between the amount of %EWL and gene expression level, with the effect of the covariates (sex, diabetes status at surgery and months between recording times of preop and postop weights) removed. The partial correlation for each gene between gene expression and %EWL given a set of the covariates was computed by the correlation between the residuals resulting from the linear regression of gene expression with the covariates and of %EWL with the same covariates, respectively. Multiple tests were controlled by the false discovery rate (FDR), the expected proportion of false positives among the tests declared significant (false plus true). 17 The raw P-values were adjusted using the Benjamini and Hochberg (FDR) method. 17 An FDR adjusted P-value o0.05 was considered as significant. On the basis of the distribution of P-values in t-test, the mixture model approach was used to estimate the number of genes with a real difference in expression levels between the two distinct groups by fitting the log-likelihood function of a mixture model and to estimate the posterior probability that a gene is a true positive. 18 The posterior probability is the Bayesian probability that a gene with a given frequentist P-value or smaller is truly different between the two groups being studied. In addition to the FDR-adjusted P-values, the posterior probabilities were used to prioritize genes in order of significance. We used web-based DAVID (http://david.abcc.ncifcrf.gov/home.jsp) to classify the gene expression profile according to functional annotation of each significant gene.
Pathway/network analysis
The jubilant biosys pathways analysis tool PathArt (http:// www.jubilantbiosys.com) was used for pathway analysis. This tool incorporates a human curated database containing pathways and diseases information based on published data in scientific journals. This database is updated quarterly and contains to date almost 50 000 interactions from over 2000 pathways. The statistical significance of the enrichment of a pathway is defined as the likelihood that the number of genes from our data belonging to the given pathway is random. The PathArt software utilizes the w 2 -test to examine the significance of the association between two data sets (our gene list vs reference gene list) in a 2 Â 2 contingency table. The P-value for the test is computed as if the odds ratio between genes in the pathway and genes not in the pathway among our gene set and the reference gene set equals to 1. The quality of the reference database is affecting the P-value of such a test and it is expected that the statistical significance value will change when the reference database is updated in the future. To alleviate such concerns, we have only shown pathway enrichments with a P-value of less than 0.01 and with a minimum of three genes from our results involved. It also should be noted that low abundant genes that cannot be detected from microarray experiments are not included in the statistical calculation and therefore the values cannot be taken as absolute but rather as relative. They allow us to identify the most significant pathways to guide validation experiments. Network analysis was performed using ingenuity pathways analysis (http://www.ingenuity.com/ products/pathways_analysis.html).
Ingenuity pathways analysis allows investigators to grow a network of elements, proteins and small molecules that have been shown to be associated from a literature database. Starting from our list of genes whose expression has been shown to be associated with %EWL after RYGB surgery, the ingenuity pathways analysis database was queried for connections between the genes. Subsequently, additional queries were preformed to grow the network with additional components considered as immediate neighbors.
Results
Subject characteristics
Clinical data on 27 subjects before and after surgery are shown in Table 1 Overview of gene expression patterns associated with RYGB-induced EWL We compared gene expression patterns between the two weight loss groups (%EWL-high vs %EWL-low). Among 22 283 transcripts, 622 (2.79%) transcripts passed the twofold filtering on FDR-adjusted P-value o0.05 and partial correlation coefficient P-value o0.05. The 622 transcripts were not only significantly differentially expressed between the two distinct weight loss groups but also their expression was highly correlated with the %EWL. Table 2 lists the 79 most significant genes in the order of P-values and posterior probabilities. Functional classes were assigned according to the biological function of each gene using DAVID (Table 3) . RYGB-induced weight loss outcomes appeared to be associated with genes involved in several different pathways, particularly glycerolipid metabolism, apoptosis and breast cancer. The following subsections provide gene lists according to biological functions.
Metabolic mechanism genes
Analysis of microarray data revealed that most metabolismrelated genes were expressed at significantly higher levels in subjects who had the least EWL (Po0.05). The genes included acyl-coenzyme A oxidase 1 (ACOX1), protein kinase, AMP-activated, b-1 non-catalytic subunit (PRKAB1), growth hormone releasing hormone receptor (GHRHR), glutamate dehydrogenase 1 (GLUD1), fucosyltransferase 2 (FUT2), hemochromatosis (HFE) and calcium/ calmodulin-dependent protein kinase II-b (CAMK2B) ( Table 2) . Specifically, ACOX1, involved in regulating fatty acid catabolism in adipose tissue, was associated with RYGBinduced weight loss. ACOX1 is a peroxisomal enzyme, which plays a major role in b-oxidation and docosahexaenoic acid synthesis. It is likely that the differences in the capacity for b-oxidation or docosahexaenoic acid synthesis influence postoperative body weight loss or gain. Protein kinase, AMPactivated, b-1 noncatalytic subunit (PRKAB1) is a regulator of AMP-activated protein kinase (AMPK) activity and is involved in regulating biosynthesis of fatty acid and cholesterol. 19, 20 Phosphodiesterase 3A cGMP-inhibited (PDE 3A) known to be expressed in adipose tissue, is involved in lipid metabolism. 21 Growth hormone-releasing hormone receptor (GHRHR) leads to synthesis and release of growth hormone. Growth hormone influences both height and overall body composition, with increased levels promoting increased muscle mass and decreased fat mass. Mutations in GHRHR have been found to be associated with isolated growth hormone deficiency, also known as Dwarfism of Sindh, as clinical characteristic. A genetic association study has shown that heterozygosity for a GHRHR mutation is associated with changes in body composition and possibly an increase in insulin sensitivity. 22 Glutamate dehydrogenase 1 is involved in glutamate catabolism. The activated glutamate dehydrogenase enhances oxidation of glutamate and, in turn, increases the regulation of insulin secretion. 23 Fucosyltransferase 2 is involved in carbohydrate metabolism and protein amino-acid glycosylation. 24, 25 Although most publications associate the hemochromatosis (HFE) gene and mutations with iron accumulation, the correlation of HFE mRNA with weight loss is consistent with a study in spontaneously obese mice that revealed a highly significant correlation between adipose tissue HFE expression and fat mass. 26, 27 CAMK2B has been
shown to have a role in regulating skeletal muscle function and metabolism during exercise in humans. 28 Those genes provide evidence of the possibility that the expression of genes involved in metabolic mechanisms, particularly in the regulation of fatty acid catabolism, induces sensitivity to RYGB, which results in postoperative weight loss.
Physiological mechanism genes
Of the significantly differentially expressed genes in response to RYGB-induced %EWL, several genes are involved in areas of human physiology including neurophysiology, sociophysiology, myophsiology, bone physiology, cardiovascular physiology and cell physiology. The genes, GABRA5, GYPA, GAL (galanin), and CAMK2B known to be involved in regulation of neuronal functions, expressed higher in %EWL-low than in %EWL-high. g-aminobutyric acid A receptor, a-5 (GABRA5) was found to be associated with bipolar disorder, also known as manic-depressive illness. 29, 30 Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and behavior and their symptoms are caused by an imbalance of key chemicals and neurotransmitters in brain. People with bipolar disorder often have abnormal thyroid gland function, which in turn leads to abnormal appetite. 31 GAL has multiple biological effects.
GAL plays an important role in regulating food and water intake behavior and is related to neuroendocrine functions. 32 GAL has also been shown to increase the levels of growth hormone, prolactine and luteining hormones, to inhibit glucose-induced insulin release and to affect gastrointestinal motility. 33 A study suggested that increased expression of CAMK2B may lead to abnormal neurodevelopment such as schizophrenia and depression. 34 CAMK2B
expression was higher in patients of %EWL-low than those
Gastric bypass-induced weight loss and gene expression profiles K Kim et al Gastric bypass-induced weight loss and gene expression profiles K Kim et al of %EWL-high. ATP2A2 (ATPase, Ca þ þ transporting, cardiac muscle, slow twitch 2) is found to involved in regulation activity in human myocardium. 35 ATP2A2 gene expressed higher in %EWL-high than in %EWL-low. Exostoses (multiple) 1 (EXT1) has a role in bone biology and in regulating bone density. 36 Androgen receptor (AR) gene affects on muscle and fat mass through an AR-mediated pathway. 37 AR polymorphism was found to be associated with bone mineral density and increased risk of osteoporosis in postmenopausal women. 38, 39 AR gene is also associated with the development and progression of a various type of cancer including breast, ovarian, prostate and gastric cancer. 40, 41 Both exostoses (multiple) 1 (EXT1) and AR expressed lower in %EWL-high than in %EWL-low. MYST4 (MYST histone acetyltransferase (monocytic leukemia) 4) has found to have a role in cellular aging. 42, 43 MYST4 gene expression was higher in %EWL-low than %EWL-high. CD44 antigen (CD44) has a functional role in the smooth muscle cells' response to the metabolic and hormonal disorders of diabetes. 44 Cancer biology genes Of the significantly expressed genes, we found candidates for proto-oncogenes that can become an oncogene due to the increased expression or mutations. Wingless-type mouse mammary tumor virus (MMTV) integration site family, member 3 (WNT3) has been implicated in oncogenesis of human breast, rectal, lung and gastric cancer through activation of the WNT-b-catenin-transcription factor (TCF) signaling pathway and in several developmental processes. 45, 46 Indian hedgehog homolog is involved in the development of the enteric nervous system. 47 Increased hedgehog signaling affects a wide range of digestive tract tumors including most of those originating in the esophagus, stomach and pancreas. 48 Also, van den Brink et al. 49 discovered that indian hedgehog homolog is an antagonist of WNT signaling in colonic epithelial cell differentiation. 49 CKLF-like MARVEL transmembrane domain containing 8 has a role of a negative regulator of epidermal growth factorinduced signaling and thus has been considered as a novel therapeutic gene for epidermal growth factor receptortargeted anticancer gene therapy. 50 High-mobility group nucleosome-binding domain 1 increases the cellular sensitivity to ionizing radiation and tumorgenicity. 51 CD44
antigen (CD44) has a functional role in the inflammatory process and tumor susceptibility. 52 ADARB1 (adenosine deaminase, RNA-specific, B1) is responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. As clinical phenotype, ADARB1 plays a role in editing hepatitis delta virus at the amber/W site during hepatitis delta virus infection. This table lists selected genes whose expression highly differentiated between the two weight loss groups. FC and FDR-adjusted P-value using Benjamini and Hochberg method (FDR P-value) of each gene were obtained by comparing %EWL-high with %EWL-low. Partial correlation coefficient and its P-value of each gene were obtained as a summary of the magnitude of the linear association between gene expression level and EWL when the covariates were fixed and its significance, respectively.
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Pathway analysis
We used statistical tools to analyze signaling and metabolic pathways encompassed by the most significant 622 genes, passing the two-fold filtering on FDR-adjusted P-value o0.05 and partial correlation coefficient P-value o0.05. Using the Jubilant PathArt database, we identified pathways that were significantly enriched in the 622 genes list (Table 4 ). The most significant signaling pathway is fatty acid synthetase (FAS) signaling pathway in the apoptosis context with eight genes represented in our data set (ANAPC2, CASP2, CDC27, CRADD, HNRPC, HTATSF1, SP100 and TMPO) with a significance P-value ¼ 0.00001. Among metabolism pathways, glycerolipid metabolism pathway is significantly enriched (P-value ¼ 0.00029) with five genes represented (PAFAH2 (platelet-activating factor acetylhydrolase 2), ALPP (alkaline phosphatase, placental), ACHE (acetylcholinesterase), AGPS (Alkylglycerone-phosphate synthase) and aldehyde dehydrogenase 3 family, member B1 (ALDH3B1). PAFAH2 is involved in lipid catabolic process and has a role in phospholipid binding. 54 All four other genes are involved in lipid biosynthesis: ALPP is a glycerophosphatase, which induces arachidonic acid release, 55 ACHE is an apoptosisrelated ACHE with affinities for liposomes, 56 AGPS is an alkylglycerone-phosphate synthase involved with the peroxisome 57 and ALDH3B1 is an aldehyde dehydrogenase involved associated with lipid peroxidation. 58 Other metabolic pathways are not significantly enriched at P-value o0.01. Although not in a significant pathway, there are several other additional genes in the 622 genes list whose expression has been shown to be associated with %EWL after RYGB surgery and that are involved in lipid metabolism such as PDE3A, ACOX1 and PRKAB1 (Figure 2 ).
Discussion
This study is the first comprehensive correlation of perioperative gene expression with EWL after RYGB surgery. Other investigators have demonstrated correlations of one or a few genes, but have not conducted exhaustive microarray studies. Our results demonstrate 'proof of principal'Fperioperative adipose tissue gene expression provides important predictive information. Although the ability to predict future weight loss with omental adipose tissue samples does not have immediate clinical utility, the present data suggest that samples from other more accessible tissues should be examined for correlations with weight loss. Specifically, our microarray data demonstrated that genes in fatty acid and lipid metabolism were significantly correlated with postoperative body weight loss. Most interestingly, this includes genes for glycerolipid syntheses that are directly involved in regulating adipose tissue fat stores. These genes provide evidence of the possibility that expression of the genes involved in metabolic mechanisms, particularly in the regulation of fatty acid catabolism, induces response to RYGB, which results in weight loss or gain following surgery over the long term. In addition, the expression of neuronal function-regulated genes was significantly correlated with postoperative weight loss. It is possible that the increased expression of those genes in %EWL-low in comparison with %EWL-high stimulates severe shifts in eating behavior and/or depression such that Gastric bypass-induced weight loss and gene expression profiles K Kim et al behavior altering can not only prevent stable weight loss after surgery in a long term but also promote weight regain after a short period following the operation. Further study is needed to elucidate a mechanism by which neuronal genes influence changes in eating behavior following surgery and in turn result in postoperative weight loss. Lastly, oncogenes that can contribute to the development of cancer due to alternation in expression were differentially expressed between the two weight loss groups. This observation suggests that genes may have pleiotropic effects on both cancer and weight. Our pathway analysis revealed a great number of signaling pathways that were significantly enriched in our data set, underlining the impact on the results of gastric bypass surgery. Of specific interest to our study is the demonstrated unique impact of the regulation of genes in lipid metabolism on weight loss. Figure 2 exhibits a network involving the lipid metabolism genes. Most of the genes in the network have been shown to clearly link to obesity and other metabolic disorders. 59 The possible involvement of several signaling molecules and pathways in weight loss implies that RYGB-induced weight loss results not only from the mechanical effects of restricting food intake or calorie absorption but also physiological effects. The discovery and characterization of those genes in weight loss regulatory pathways will give insights to the mechanisms by which RYGB induces weight loss and also to the physiological mechanism of obesity. Our clinical data demonstrated that individual responses to RYGB postoperatively varied considerably with %EWL ranging from 25 to 116% (n ¼ 27). On the basis of this observation, we hypothesized that the differences in perioperative adipose tissue gene expression contribute, at least in part, to response differences of RYGB patients. Differences between patients may be due to environmental, behavioral and metabolic factors that influence energy balance that cannot be assessed in this study. For instance, changes in gene expression may be indirectly related with weight loss because of the linked genes that indirectly influence the expression of the genes that regulate body weight.
Whole genome expression profiles enabled us to examine the roles of thousands of genes simultaneously in people with differing responses to surgery. Studies have shown that adipose tissue-expressed genes that influence obesity and its comorbidities can be identified by mRNA expression profiles. 60, 61 Age, sex, BMI and psychosocial status are correlated with outcomes from RYGB. Our data identify expressed genes in omental adipose tissue that are also correlated with weight response to RYGB surgery. Adipose-expressed gene levels may differ from person to person as a result of environmental or genetic differences. A recent paper analyzing 23 720 transcripts in blood and Abbreviations: EGF, epidermal growth factor, IL, interleukin. The number of hits is the number of genes present in both our significant genes set and the named reference set.
Gastric bypass-induced weight loss and gene expression profiles K Kim et al adipose of more than 1000 people living in Iceland has shown that 72% of adipose-expressed genes are correlated with BMI. 62 The authors also demonstrated that more than 70% of the gene expression levels were heritable in families. Genes may have heritable mRNA levels either due to variants near the gene (cis) or distant variant alleles (trans). The authors then showed that more than 1300 of these genes are cis-regulated, presumably because of polymorphisms in or adjacent to these genes. The results of Emilsson et al. 62 are consistent with the hypothesis that perioperative gene expression predicts long-term weight loss because genetic differences between patients influence the expression both peri and postoperatively. We have not directly tested this hypothesis, in part because omental adipose can only be collected during surgery. We also cannot distinguish whether or not measured expression differences are due to cis or trans effects. We also cannot rule out the hypothesis that the differences in gene expression in the patients reflect environmental differences that also influence weight loss, such as diet preferences and psychological status. These environmental differences could influence both peri and postoperative gene expression. Despite the existence of these several confounding factors, it is highly possible that the expression differences correlated with EWL have a biological (heritable) basis. We should note that this study does not establish the mechanisms by which RYGB surgery influences weight loss but demonstrates the feasibility of adipose tissue gene expression profiles as a means for biomarker discovery predictive of RYGB outcomes. Emilsson et al. also demonstrated that although mRNA from blood samples can be correlated with BMI, adipose tissue has about 34-times more correlated transcripts. 62 Thus, our results suggest that the adipose tissue biomarkers have excellent potential as predictors to assess long-term efficacy of RYGB (weight loss maintenance), which may lead to clinical utility. We have identified a set of significant genes involved in metabolic pathways, as this should be enough to demonstrate proof of principal that predictive genes exist and are expressed in adipose tissue. However, this study has limitations. We studied gene expression in perisurgical omental adipose in this project, but there are more accessible tissues (white blood cells, adipose or muscle punch biopsies and liposuctioned adipose). Different adipose tissues may provide divergent information about gene expression profiles predictive of postoperative weight loss. We chose Gastric bypass-induced weight loss and gene expression profiles K Kim et al omental adipose because of clinical utility without any surgical complications under the current surgical protocols and abundance of expression so that the given small sample size would yield the necessary power for microarray analysis.
The inaccessibility/unavailability of other tissues including liver, heart and brain in humans limits gene expression analysis approaches to correlating clinical endpoints to physiological functions. Although known obesity gene mutations cause less than 5% of obesity (BMI435 kg/m 2 ), individuals with mutations (for example, MC4R and PPARg) introduce an obvious bias. 63, 64 This study did not test participants for the known mutations. Nonetheless, this study provides enough collective information to show the feasibility of using microarrays to identify biomarkers predictive of postoperative weight loss. We regard this study as a step toward this task, which can help to provide the basis for a number of important hypotheses. However, our findings were drawn from a small sized microarray experiment, and some of the statistically significant findings identified may be due to chance. Rigorous validation of microarray findings needs to be carried out with an adequate (larger) sample size in future studies. The general guidelines for a successful microarray study are discussed elsewhere. 65 Further study is needed to evaluate metabolic and other functional pathways of the genes identified in this study and thereby increase our understanding of the role of specific genes in RYGB-induced weight loss and obesity.
